CORRECTING & REPLACING -- MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism

Rhea-AI Summary

MBX (Nasdaq: MBX) completed an End-of-Phase 2 meeting with the FDA and plans to start a randomized Phase 3 trial of once-weekly canvuparatide for chronic hypoparathyroidism in Q3 2026. The Phase 3 design: ~160 patients randomized 3:1, 4-week fixed dose (600 micrograms), 18-week titration, 4-week maintenance, primary analysis at Week 26, then open-label extension. The company also received orphan drug designation from the European Medicines Agency for chronic hypoparathyroidism.

Positive

• End-of-Phase 2 meeting outcome supports planned Phase 3 initiation in Q3 2026
• Phase 3 protocol selected: ~160 patients, randomized 3:1, primary analysis at Week 26
• Orphan drug designation from European Medicines Agency for chronic hypoparathyroidism

Negative

• None.

News Market Reaction – MBX

-8.54%

16 alerts

-8.54% News Effect

-2.9% Trough in 2 hr 38 min

-$120M Valuation Impact

$1.29B Market Cap

1.3x Rel. Volume

On the day this news was published, MBX declined 8.54%, reflecting a notable negative market reaction. Argus tracked a trough of -2.9% from its starting point during tracking. Our momentum scanner triggered 16 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $120M from the company's valuation, bringing the market cap to $1.29B at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Phase 3 start: Q3 2026 Phase 3 patients: approximately 160 patients Randomization ratio: 3:1 canvuparatide:placebo +5 more

8 metrics

Phase 3 start Q3 2026 Planned initiation of Phase 3 canvuparatide trial

Phase 3 patients approximately 160 patients Planned enrollment in double-blind placebo-controlled trial

Randomization ratio 3:1 canvuparatide:placebo Phase 3 trial allocation

Fixed-dose period 4 weeks Initial fixed dose phase at 600 micrograms

Canvuparatide dose 600 micrograms Once-weekly dose during fixed-dose period

Dose-titration period 18 weeks Phase 3 dose-titration phase

Maintenance period 4 weeks Maintenance phase before primary analysis

Primary analysis timepoint Week 26 Assessment of primary efficacy endpoint

Market Reality Check

Price: $29.01 Vol: Volume 591,572 is 1.11x t...

normal vol

$29.01 Last Close

Volume Volume 591,572 is 1.11x the 20-day average of 533,648, showing slightly elevated trading activity. normal

Technical Shares trade above the 200-day MA of $21.61 at a pre-news price of $30.55, despite being 31.94% below the 52-week high.

Peers on Argus

MBX was down 2.82% while peers showed mixed moves: RCKT up 4.99%, BNTC up 3.57%,...

2 Up 1 Down

MBX was down 2.82% while peers showed mixed moves: RCKT up 4.99%, BNTC up 3.57%, TECX down 9.23%. With peers not aligning directionally and scanner data flagging both up and down moves, today’s action appears more stock-specific than sector-driven.

Previous Clinical trial Reports

5 past events · Latest: Sep 22 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Sep 22	Phase 2 results	Positive	+100.0%	Phase 2 canvuparatide met primary endpoint with strong responder rates and safety.
Sep 19	Results preview	Positive	+100.0%	Announcement of upcoming Phase 2 canvuparatide topline results and investor call.
Sep 04	Phase 1 initiation	Positive	-10.3%	First participant dosed in Phase 1 obesity trial of MBX 4291 with multi-part design.
Mar 03	Phase 2 enrollment	Positive	+5.6%	Completion of enrollment in Phase 2 Avail trial of canvuparatide for hypoparathyroidism.
Jan 07	Phase 1 results	Positive	-10.3%	Positive Phase 1 topline results for MBX 1416 in post-bariatric hypoglycemia.

Pattern Detected

Clinical trial headlines for MBX have often triggered large moves, with both sharp rallies and notable selloffs, suggesting event-driven and sometimes volatile reactions to trial updates.

Recent Company History

Recent MBX news in the clinical trial category shows significant sensitivity to development milestones. Positive Phase 2 data for once-weekly canvuparatide in September 2025 and the associated topline-results announcement each saw +100% moves, while other trial updates like the MBX 4291 Phase 1 dosing on Sep 4, 2025 and MBX 1416 Phase 1 results on Jan 7, 2025 coincided with declines of -10.28% and -10.32%. The current End-of-Phase 2 outcome and Phase 3 plan continue this pattern of major, catalyst-driven clinical updates for endocrine and metabolic programs.

Historical Comparison

+37.0% avg move · In the past year, MBX released 5 clinical-trial updates averaging a 37.01% move. Clinically positive...

clinical trial

+37.0%

Average Historical Move clinical trial

In the past year, MBX released 5 clinical-trial updates averaging a 37.01% move. Clinically positive news sometimes sold off, underscoring historically volatile, event-driven trading around trial milestones.

Clinical updates show progression from Phase 2 enrollment and success for canvuparatide toward Phase 3 planning, alongside diversification into MBX 1416 and MBX 4291 programs across endocrine and metabolic indications.

Regulatory & Risk Context

Active S-3 Shelf · $400,000,000

Shelf Active

Active S-3 Shelf Registration 2025-11-06

$400,000,000 registered capacity

MBX has an active Form S-3 shelf filed on 2025-11-06 to offer up to $400,000,000 of securities, including an at-the-market program of up to $150,000,000. The shelf is currently marked as not effective in the context data, with 0 recorded usages, indicating authorized capacity but no tracked takedowns under this shelf in the provided dataset.

Market Pulse Summary

The stock moved -8.5% in the session following this news. A negative reaction despite constructive r...

Analysis

The stock moved -8.5% in the session following this news. A negative reaction despite constructive regulatory feedback would fit MBX’s pattern of occasional selloffs on otherwise positive clinical news, such as prior Phase 1 updates that saw declines near -10%. The End-of-Phase 2 meeting confirmed a Phase 3 path and outlined a 160-patient, placebo-controlled design, but expectations after earlier canvuparatide data and awareness of capital-raising capacity under the shelf registration could have contributed to pressure.

Key Terms

end-of-phase 2, phase 3, orphan drug designation, double-blind, +4 more

8 terms

end-of-phase 2 regulatory

"announced the successful completion of an End-of-Phase 2 (EOP2) meeting"

End-of-phase 2 is the development milestone when a drug or medical treatment completes its mid-stage human testing and the sponsor and regulators review the results to decide whether and how to proceed to larger late-stage trials. It matters to investors because this review signals whether the product showed enough benefit and acceptable safety to justify expensive Phase 3 studies, much like passing a major exam before committing to the final, costly year of a degree, and can materially affect a company’s value and funding needs.

phase 3 medical

"MBX remains on track to initiate Phase 3 in Q3 2026"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

orphan drug designation regulatory

"canvuparatide has been granted orphan drug designation by the European Medicines Agency"

Orphan drug designation is a special status given to medicines developed to treat rare diseases affecting only a small number of people. This status often provides benefits like faster approval processes and financial incentives, making it more attractive for companies to develop these drugs. For investors, it signals potential for exclusive market rights and reduced competition, which can impact the drug’s profitability.

double-blind medical

"The Phase 3 double-blind placebo-controlled trial will enroll approximately 160 patients"

A double-blind process means that neither the people conducting an activity nor the people involved know certain key details, such as who is receiving a treatment or a placebo. This approach helps prevent bias from influencing the results, making the outcome more trustworthy. For investors, it ensures that decisions or judgments are based on unbiased information rather than preconceived opinions or expectations.

placebo-controlled medical

"The Phase 3 double-blind placebo-controlled trial will enroll approximately 160 patients"

"Placebo-controlled" describes a testing method where one group receives the actual treatment or intervention, while another group receives a harmless, inactive version called a placebo. This approach helps determine whether the real treatment has genuine effects beyond psychological expectations. For investors, understanding this ensures confidence that reported benefits are real and not influenced by bias or false perceptions.

primary endpoint medical

"primary endpoint (including proportion of participants who achieve normal serum calcium"

The primary endpoint is the single main result a clinical study is designed to measure to decide if a treatment works, like the finish line in a race that tells you who won. Investors care because meeting or missing this goal drives regulatory decisions, future sales expectations and stock value — it turns trial data into a clear yes-or-no signal about a drug’s commercial prospects.

secondary endpoints medical

"key secondary endpoints (including normalization of urinary calcium)"

Secondary endpoints are the additional outcomes measured in a clinical study beyond the main goal; they can include effects on symptoms, quality of life, safety measures, or other health indicators. For investors, they matter because positive or negative secondary results can strengthen or weaken the overall story about a treatment’s benefits and risks—like seeing not only that a car reaches its destination (primary goal) but also how comfortable and efficient the ride was (secondary findings).

open label extension medical

"transition to an open label extension to assess both long-term safety"

An open-label extension is a follow-on phase of a clinical trial where participants keep receiving the experimental drug and both doctors and patients know what treatment is being given. It matters to investors because it produces longer-term safety and effectiveness information, helps regulators and companies assess ongoing benefits or risks, and can indicate whether a therapy has staying commercial value — like an extended test drive revealing durability and real-world performance.

AI-generated analysis. Not financial advice.

Following End-of-Phase 2 meeting, MBX remains on track to initiate Phase 3 in Q3 2026

In the fourth paragraph, we are replacing milligrams with micrograms. The corrected press release follows.

CARMEL, Ind., March 09, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the successful completion of an End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA) to discuss the overall Phase 3 trial design for once-weekly canvuparatide for the treatment of chronic hypoparathyroidism (HP).

“We are very encouraged by the outcome of our End-of-Phase 2 meeting and the constructive feedback supporting our planned Phase 3 trial for canvuparatide,” said Sam Azoulay, M.D., Chief Medical Officer of MBX Biosciences. “We believe canvuparatide has the potential to establish a new standard of care in hypoparathyroidism by restoring physiologic PTH activity and maintaining normocalcemia with the convenience of a patient-centric once-weekly dosing regimen. Feedback from physicians and patients has reinforced strong interest in a less burdensome treatment option, which we believe should translate into enthusiastic enrollment in the Phase 3 trial, and we look forward to enrolling the first patient in Q3 2026 now that we have confirmed the regulatory path toward an NDA submission.”

Based on feedback from the FDA, MBX plans to advance once-weekly canvuparatide into a Phase 3 trial in the third quarter of 2026. Phase 3 trial design elements have now been selected, including the number of patients, primary endpoint (including proportion of participants who achieve normal serum calcium and independence from conventional therapy) and key secondary endpoints (including normalization of urinary calcium), as well as dose selection, titration schedule and duration of the study.

The Phase 3 double-blind placebo-controlled trial will enroll approximately 160 patients, randomized in a 3:1 ratio to receive canvuparatide or placebo. Following randomization, there will be a 4-week fixed dose period of 600 micrograms of canvuparatide (or placebo), followed by an 18-week dose-titration period, and a 4-week maintenance period. The primary efficacy analysis will be assessed at Week 26, followed by a transition to an open label extension to assess both long-term safety and durability of effect.

The Company also announced today that once-weekly canvuparatide has been granted orphan drug designation by the European Medicines Agency for the treatment of chronic hypoparathyroidism, supporting its continued clinical development in Europe.

About Canvuparatide
Canvuparatide is a parathyroid hormone peptide prodrug that is designed as a potential long-acting hormone replacement therapy for the treatment of HP. Leveraging the company’s proprietary Precision Endocrine Peptide™ (PEP™) platform technology, canvuparatide was designed to provide convenient, once-weekly administration and a continuous, infusion-like PTH exposure with lower daily peak-to-trough ratios than observed with daily PTH dosing regimens. Canvuparatide received orphan drug designation from the U.S. Food and Drug Administration for the treatment of HP.

About Hypoparathyroidism (HP)
HP is a rare endocrine disease caused by a deficiency of parathyroid hormone (PTH) released by the parathyroid glands that results in decreased calcium levels in the blood, leading to hypocalcemia. Hypocalcemia can cause a variety of symptoms, such as muscle cramping or spasm, tingling, and neurological symptoms such as depression, confusion, and cognitive impairment. More serious complications can occur, including seizures and cardiac arrhythmia. HP can interfere with daily activities, negatively impacting the quality of life for patients. We estimate that HP affects more than 250,000 individuals in the U.S. and Europe. The current standard of care for HP does not address the underlying cause of the disease, PTH deficiency, and consists primarily of high doses of oral calcium and active vitamin D supplements.

About MBX Biosciences
MBX Biosciences is a biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies based on its proprietary PEP™ platform, for the treatment of endocrine and metabolic disorders. The Company is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. The Company’s pipeline includes canvuparatide (MBX 2109) for the treatment of chronic hypoparathyroidism (HP) preparing for Phase 3 development; an obesity portfolio that includes MBX 4291 in Phase 1 development, as well as multiple discovery and pre-clinical obesity candidates; and imapextide (MBX 1416) for the treatment of post-bariatric hypoglycemia (PBH) in Phase 2 development. The Company is based in Carmel, Indiana. To learn more, please visit the Company website at www.mbxbio.com and follow it on LinkedIn.

Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, express or implied statements regarding: MBX Biosciences’ expectations regarding the design of a Phase 3 trial; expectations regarding timing, including plans to initiate a Phase 3 clinical trial in Q3 2026; the potential for canvuparatide to be a new standard of care for HP; the potential market opportunity in HP; orphan drug designation and the intended benefits of such designation; and the unmet need for a new treatment option.

Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect MBX Biosciences’ business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to the Company’s research and development activities; MBX Biosciences’ ability to execute on its strategy including obtaining the requisite regulatory approvals on the expected timeline, if at all; uncertainties relating to preclinical and clinical development activities; the Company’s dependence on third parties to conduct clinical trials, manufacture its product candidates and develop and commercialize its product candidates, if approved; MBX Biosciences’ ability to attract, integrate and retain key personnel; risks related to the Company’s financial condition and need for substantial additional funds in order to complete development activities and commercialize a product candidate, if approved; risks related to regulatory developments and approval processes of the U.S. Food and Drug Administration and comparable foreign regulatory authorities; risks related to establishing and maintaining MBX Biosciences’ intellectual property protections; risks related to the competitive landscape for MBX Biosciences’ product candidates; and final audit adjustments and other developments that may arise that would cause MBX Biosciences’ expectations with respect to the estimate of cash, cash equivalents and marketable securities as of December 31, 2025 to differ, perhaps materially, from the financial results that will be reflected in MBX Biosciences’ audited consolidated financial statements for the fiscal year ended December 31, 2025; as well as other risks described in “Risk Factors,” in MBX Biosciences’ Quarterly Report on Form 10-Q for the three months ended September 30, 2025, Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission (SEC), as well as subsequent filings with the SEC. MBX Biosciences expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law, and claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

MBX Biosciences uses and intends to continue to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the Company's Investor Relations website, in addition to following the Company's press releases, SEC filings, public conference calls, presentations, and webcasts.

Media Contact:
George Shea
We. Communications
gshea@wecommunications.com

Investor Contact:
Jim DeNike
MBX Biosciences
jdenike@mbxbio.com

FAQ

When will MBX (MBX) begin Phase 3 for canvuparatide?

MBX plans to begin the Phase 3 trial in Q3 2026. According to the company, this follows a successful End-of-Phase 2 FDA meeting and confirmation of the regulatory path toward an NDA submission.

What is the Phase 3 design for canvuparatide (MBX) in hypoparathyroidism?

The Phase 3 trial will enroll ~160 patients randomized 3:1 to drug or placebo. According to the company, it includes a 4-week 600 microgram fixed dose, 18-week titration, 4-week maintenance, and primary analysis at Week 26.

What are the primary and key secondary endpoints in MBX's Phase 3 canvuparatide trial?

The primary endpoint includes achieving normal serum calcium and independence from conventional therapy. According to the company, key secondary endpoints include normalization of urinary calcium and other pre-specified measures.

How will MBX assess long-term safety and durability for canvuparatide after Phase 3?

MBX will transition participants to an open-label extension after Week 26 to assess long-term safety and durability. According to the company, this follow-up aims to monitor sustained effect and safety beyond the randomized period.

Does canvuparatide have regulatory recognition in Europe for hypoparathyroidism?

Yes, canvuparatide received orphan drug designation from the European Medicines Agency for chronic hypoparathyroidism. According to the company, this designation supports continued clinical development in Europe.